sglt2 inhibitors vs glp 1 agonists or GLP-1 receptor as second-line therapy in | VHRM Cardiovascular benefits of SGLT2 inhibitors
Description
Side effect profiles differ patients may tolerate semaglutide better
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial
3 Future studies are needed to determine whether this class of medications inhibits progression from nonexudative to neovascular or late atrophic stages of AMD
FTC Affiliate Disclosure: This article contains affiliate links
Ceriello A, Novials A, Canivell S, La Sala L, Pujadas G, Esposito K, Testa R, Bucciarelli L, Rondinelli M, Genovese S: Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes
